

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/551,998
Filing Date	October 5, 2006
First Named Inventor	Kai SCHIEMANN, et al.
Group Art Unit	1626
Examiner Name	Yong Liang Chu
Attorney Docket Number	MERCK-3073

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Dated of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	2004/0034083		Stephenson et al.	02-19-2004
	A2	2002/0091116		Zhu et al.	07-2002
	A3	2007/0010531		Schadt et al.	01-2007
	A4	2006/0264419		Schiemann et al.	11-2006
	A5	2006/0276650		Schadt et al.	12-7-2006
	A6	4,258,047		Gante et al.	03-24-1981
	A7	3,926,999		Poetsch	12-16-1975
	A8	2007/0093492		Jiaang et al.	04-2007
	A9	2001/0044445		Bamaung et al.	11-2001
	A10	7,067,507		Pulley et al.	06-2006
	A11	4,631,343		Beck, James R.	12-1986
	A12	2005/023979		Gaster et al.	10-27-2005
	A13	6,100,259		Xiang et al.	08-08-2000
	A14	6,407,238		Baron et al.	06-18-2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear	†*
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	03088958		Maziasz Timothy J.	10-30-2003		A1
	B2	WO	0132626		Gaster Laramie Mary	05-10-2001		A12
	B3	WO	9831227		Schiemann et al.	07-1998		A13
	B4	WO	03031435		Schiemann et al.	04-2003		
	B5	DE	2906252		Merck Patent GmbH	08-28-1980		A6
	B6	DE	2201889		Merck Patent GmbH	07-19-1973		A7
	B7	WO	0132627		Baron et al.	05-10-2001		A14

Examiner
SignatureDate
Considered

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/551,998
Filing Date	October 5, 2006
First Named Inventor	Kai SCHIEMANN, et al.
Group Art Unit	1626
Examiner Name	Yong Liang Chu
Attorney Docket Number	MERCK-3073

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Ross et al., Expert Opinion on Therapeutic Patents, 2003, 13(10), 1491-99.	
	C2	DATABASE BEILSTEIN "ONLINE! BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; JUNE 27, 1988, XP002283830.	
	C3	Vippagunta et al., Advanced Drug Delivery Reviews, 2001, 48, 3-26.	
	C4	"Premenstrual syndrome-Womens health and Medical Information in Medicinenet.com", http://www.medicinenet.com/premenstrual_syndrome/page5.htm , accessed September 19, 2007.	
	C5	"Amyotrophic Lateral sclerosis information page: National Institute of Neurological Disorders and Stroke (NINDS)", http://www.ninds.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm , accessed September 19, 2007.	
	C6	"Obsessive-compulsive behaviors and disorders: symptoms, treatment, and support", http://www.helpguide.org/mental/obsessive_compulsive_disorder_ocd.htm , accessed September 19, 2007.	
	C7	Journal of Clinical Psychiatry, 1999, 60, 1-8.	
	C8	Crow, S. Expert Opinion on Investigational Drugs, 1997, 6(4), 427-36.	
	C9	Non Final Rejection dated May 7, 2007 - U.S. application no. 10/552,064 filed October 5, 2005 (Publication No. US-2007-0010531-A1).	
	C10	Non Final Rejection dated September 29, 2007 - U.S. application no. 10/552,064 filed October 5, 2005 (Publication No. US-2007-0010531-A1).	
	C11	Final Rejection dated July 9, 2008 - U.S. application no. 10/552,064 filed October 5, 2005 (Publication No. US-2007-0010531-A1).	
	C12	Non Final Rejection dated August 25, 2008 - U.S. application no. 10/552,065 filed October 5, 2005 (Publication No. US-2006-0264419-A1).	
	C13	Non Final Rejection dated January 22, 2008 - U.S. application no. 10/551,905 filed October 5, 2005 (Publication No. US-2006-0276650-A1).	
	C14	Final Rejection dated August 8, 2008 - U.S. application no. 10/551,905 filed October 5, 2005 (Publication No. US-2006-0276650-A1).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.